A recent study demonstrated that semaglutide significantly reduces the risk of major kidney disease events, cardiovascular outcomes, and all-cause mortality in patients with type 2 diabetes and chronic kidney disease. The trial data, presented at the 61st European Renal Association (ERA) Congress, paves the way for new treatment strategies.
“The use of semaglutide in people with type 2 diabetes and chronic kidney disease can lower the risk of major kidney outcomes and reduce the risk of cardiovascular events, cardiovascular death and all-cause death,” noted Professor Vlado Perkovic. These benefits signify a profound clinical impact saving kidneys, hearts and lives, for patients with type 2 diabetes and chronic kidney disease. Additionally, the reassuring safety findings further support the strong potential value of semaglutide in this population.”
Perkovic, who presented the research, is Dean of Medicine and Health and Scientia Professor at UNSW Sydney. Study results were also published in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2403347.
The FLOW (Evaluate Renal Function with Semaglutide Once Weekly) study was designed to assess the efficacy and safety of semaglutide. Patients either received semaglutide 1.0 mg once weekly or placebo. In the semaglutide group, kidney function declined more slowly than in the group given a placebo. Participants given semaglutide had a 24% lower risk of cardiovascular death or poor kidney outcomes. The risk of major cardiovascular events decreased by 18%, and of death from any cause mortality declined by 20%.
“These findings offer great promise in reshaping treatment strategies for individuals at high risk of diabetes-related complications, offering a new avenue for kidney and cardiovascular protection,” Perkovic stated.
The ERA Congress news release is available here: https://www.era-online.org/wp-content/uploads/2024/05/ERA_Congress_Press_Release_FLOW_Perkovic.pdf
Comments